iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Shares Shorted: Short Interest Up 847.2% in September

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) was the target of a significant growth in short interest during the month of September. As of September 30th, there was short interest totaling 218,618 shares, a growth of 847.2% from the September 15th total of 23,081 shares. Approximately 2.9% of the company’s shares are short sold. Based on an average trading volume of 209,979 shares, the days-to-cover ratio is presently 1.0 days.

iShares Genomics Immunology and Healthcare ETF Stock Performance

Shares of IDNA stock traded up $1.75 during mid-day trading on Friday, hitting $42.17. The company’s stock had a trading volume of 151,574 shares, compared to its average volume of 67,732. The company’s fifty day simple moving average is $38.99 and its 200-day simple moving average is $33.57. iShares Genomics Immunology and Healthcare ETF has a 52 week low of $23.90 and a 52 week high of $43.44. The company has a market cap of $314.17 million, a PE ratio of 14.76 and a beta of 0.94.

Institutional Trading of iShares Genomics Immunology and Healthcare ETF

An institutional investor recently bought a new stake in iShares Genomics Immunology and Healthcare ETF stock. NewEdge Advisors LLC bought a new stake in iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 961 shares of the company’s stock, valued at approximately $32,000.

iShares Genomics Immunology and Healthcare ETF Company Profile

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.